Sensitization of the Trigeminovascular Pathway: Perspective and Implications to Migraine Pathophysiology

Citation
Bernstein, Carolyn, and Rami Burstein. 2012. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. Journal of Clinical Neurology 8(2): 89-99.

Published Version
doi:10.3988/jcn.2012.8.2.89

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10454625

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Introduction

Migraine is a heterogeneous neurological disorder characterized as a recurring, episodic, unilateral headache. Migraine pain usually throbs and is typically intensified by physical activities that increase intracranial pressure (such as bending over or coughing). The pain is associated with high incidence of nausea and occurrence of hypersensitivity to light (photophobia) and noise (phonophobia). Symptoms of lesser prevalence include, aversion to odors (osmophobia), vomiting, fatigue, red eyes, tearing, nasal congestion, frequent yawning. A migraine attack may be precipitated by endogenous factors (i.e., hormonal changes, psychosocial stress, sleep deficit or surplus, hunger), or by exogenous factors (i.e., certain kinds of food: stimulation of different sensory modalities). An attack can be preceded by abnormal visual, sensory, motor and/or speech functions (migraine with aura) or start with no warning signs (migraine without aura).

Vascular Theory of Migraine-Extracranial Origin

For many years, migraine headache has been thought to be related to dilation of extracranial arteries. The theory was, as cited extensively in medical textbooks, that abnormal vasodilatation during migraine causes mechanical activation of perivascular stretch receptors, resulting in throbbing headache. This view was based on observations that extracranial...
arteries are vasodilated, edematous, and partially damaged during migraine. However, the extracranial vascular theory has fallen out of favor because clinical studies have yielded no convincing evidence for any significant extracranial vasodilation during migraine, nor have they shown that vasodilation can produce headache.

**Vascular Theory of Migraine-Intracranial Origin**

The prevailing view today is that migraine headache is a neurovascular disorder of intracranial origin that involves meningeal blood vessels and the pain fibers that innervate them. This theory has originated from reports that electrical and mechanical stimulation of dural vasculature (but not the surface of the brain) produced referred head pain in awake patients undergoing craniotomy. 1) periorbital pain - by stimulating the superior sagittal sinus or blood vessels of the floor of the anterior fossa; 2) parietal/temporal pain - by stimulating the middle meningeal artery; 3) occipital pain - by stimulating the dura at the floor of the posterior (PO) fossa, and the sigmoid, transverse and occipital sinuses. It should be emphasized that a) no sensation other than pain was evoked by stimulation of these structures; b) stimulation of non-vascular areas of the dura was largely ineffective in inducing pain sensation. These findings fit well with the pattern of dural innervation, whereby sensory nerves that originate in trigeminal and upper cervical ganglia closely follow meningeal blood vessels but not non-vascular areas of the dura. It was not until the 1980’s that the nature of dural innervation was proved to be nociceptive. We now know that the dura is richly innervated by unmyelinated (C-fibers) and thinly myelinated (Aδ fibers) axons that originate in the trigeminal ganglion and in C1-3 dorsal root ganglia and that these pain fibers contain vasoactive neuropeptides such as substance P and calcitonin gene-related peptide (CGRP). These lines of evidence promoted the theory that the headache phase of migraine is mediated by activation of nociceptors that innervate meningeal blood vessels (i.e., meningeal nociceptors), and provided the basis for developing animal models of neurovascular head pain with intracranial origin.

**Experimental Activation of Trigeminovascular Pathways**

The first animal model of neurovascular head pain employed the paradigm of electrical and/or mechanical stimulation of the dural sinuses. Using anatomical, physiological, histological and pharmaceutical techniques, such animal studies have demonstrated the presence of dura-sensitive neurons in brain and spinal cord structures, such as the medullary dorsal horn, thalamus, hypothalamus, periaqueductal gray (PAG). In the medullary dorsal horn and thalamus, the majority of these trigeminovascular neurons respond to noxious skin stimuli either preferentially (wide-dynamic range neurons) or exclusively (high-threshold neurons). Administration of anti-migraine drugs such as ergotamines, triptans, or CGRP antagonists have been shown to inhibit responses to electrical stimulation of the dura in dura-sensitive neurons in the medullary dorsal horn.

The acute stimulation of dural sinuses as a model for neurovascular head pain with intracranial origin has identified the trigeminovascular system and established the potential involvement of each of its elements in vascular headache and the associated symptoms. However, acute electrical or mechanical stimulation of the dura does not induce migraine in man, and can only evoke a short burst of activity in peripheral and central trigeminovascular neurons.

In recent years, it has become apparent that many types of prolonged or chronic pain are associated with long-lasting activation and sensitization of peripheral nociceptors and/or central nociceptive neurons in the dorsal horn. Incorporating these concepts into basic research on migraine pathophysiology, a new animal model for long-lasting headache of migraine was developed. This model involves prolonged activation and subsequent sensitization of the trigeminovascular system in response to a brief exposure of the dura to a mixture of inflammatory agents consisting of serotonin, bradykinin, histamine, and prostaglandin. These agents activate and sensitize somatic and visceral nociceptors in the rat and are potent algesics in humans, capable of inducing headache.

**Peripheral Sensitization**

Using this animal model, it was found that a brief chemical irritation of the dura activates and sensitizes meningeal nociceptors (first-order trigeminovascular neurons) over a long period of time, rendering them responsive to mechanical stimuli to which they showed only minimal or no response prior to their sensitization (Fig. 1). During migraine, such peripheral sensitization is likely to mediate the throbbing pain and its aggravation during routine physical activities such as coughing, sneezing, bending over, rapid head shake, holding one’s breath, climbing up the stairs, or walking.

By the end of migraine, when meningeal nociceptors are presumably no longer sensitized, their sensitivity to fluctuations in intracranial pressure returns to normal, and the patient no longer feels throbbing.
Central Sensitization

Medullary dorsal horn

Brief stimulation of the dura with inflammatory agents also activates and sensitizes second-order trigeminovascular neurons located in the medullary dorsal horn that receive convergent input from the dura and the skin. In this paradigm, the central trigeminovascular neurons develop hypersensitivity in the periorbital skin, manifested as increased responsiveness to mild stimuli (brush, heat, cold) to which they showed only minimal or no response prior to their sensitization (Fig. 2). The induction of central sensitization by intracranial stimulation of the dura, and the ensuing extracranial hypersensitivity was taken to suggest that a similar process occurs in patients during migraine (Fig. 3).

Extracranial hypersensitivity during migraine was first noted in 1873 and later documented in the 1950’s. At that time, extracranial hypersensitivity was ascribed to “hematomas that develop hours after onset of headache as a result of damage to vascular walls of blood vessels such as the temporal artery”, or “widespread distension of extracranial blood vessels or spasm of suboccipital scalp muscles”. The current view, however, is that extracranial hypersensitivity is a manifestation of central neuronal sensitization rather than extracranial vascular pathophysiology. Recent quantitative stimulation applied to the surface of the skin showed that pain thresholds to mechanical, heat, and cold skin stimuli decrease significantly during migraine in the majority of patients (Fig. 3A). This skin hypersensitivity, termed cutaneous allodynia, is typically found in the periorbital area on the side of the migraine headache. Patients commonly notice cutaneous allodynia during migraine when they become irritated by innocuous activities such as combing, shaving, taking a shower, wearing eyeglasses or earrings, or resting their head on the pillow on the headache side. Ipsilateral cephalic allodynia is likely to be mediated by sensitization of trigeminovascular neurons in

Fig. 1. Sensitization of peripheral trigeminovascular neuron (meningeal nociceptor) believed to mediate intracranial hypersensitivity. A: Experimental setup. B: Development of mechanical hypersensitivity over time. IS: inflammatory soup.
the medullary dorsal horn that process sensory inputs from the dura and periorbital skin.

**Thalamus**

In the course of studying cephalic allodynia during migraine, we unexpectedly found clear evidence for allodynia in remote skin areas outside the innervation territory of the trigeminal nerve (Fig. 3B).

In the discussion of that study, we proposed that ipsilateral cephalic alldynia is mediated by sensitization of dura-sensitive neurons in the medullary dorsal horn because their cutaneous receptive field is confined to innervation territory of the ipsilateral trigeminal nerve, and that extracephalic allodynia must be mediated by neurons that process sensory information from all levels of the spinal and medullary dorsal horn. Our search of such neurons focused on the thalamus since an extensive axonal mapping of sensitized trigeminovascular neurons in the spinal trigeminal nucleus revealed distinguish projections to the PO, the ventral posteromedial and the sub-parafascicular nuclei.

In 2010 we reported that topical administration of inflammatory molecules to the dura sensitized thalamic trigeminovascular neurons that process sensory information from the cranial meninges and cephalic and extracephalic skin. Sensitized thalamic neurons developed ongoing firing and exhibited hyper-responsiveness (increased response magnitude) and hypersensitivity (lower response threshold) to mechanical and thermal stimulation of extracephalic skin areas (Fig. 4).

Relevant to migraine pathophysiology was the finding that in such neurons, innocuous extracephalic skin stimuli that did not induce neuronal firing before sensitization (e.g., brush) became as effective as noxious stimuli (e.g., pinch) in triggering large bouts of activity after sensitization was established.

To understand better the transformation of migraine headache into widespread, cephalic and extracephalic alldynia, we also studied the effects of extracephalic brush and heat stimuli on thalamic activation registered by fMRI during migraine in patients with whole-body alldynia. Functional assessment of blood oxygenation level-dependent signals showed that brush and heat stimulation at the skin of the dorsum of the hand produced larger blood oxygenation level-
Central sensitization can be either activity-dependent or activity-independent. The induction of sensitization in second-order trigeminovascular neurons, using chemical stimulation of the rat dura, is activity dependent, as evidenced by lidocaine blockade of afferent inputs from the dura. Once established, however, sensitization of the second-order trigeminovascular neurons becomes activity-independent, as it can no longer be interrupted by lidocaine on the dura. Translating these findings in the context of migraine with allodynia, it appears that central sensitization depends on incoming impulses from the meninges in the early phase of the attack, and maintains itself in the absence of such sensory input later on. This view is strongly supported by the effects of the antimigraine 5-HT₁D agonists, known as triptans, on the induction and maintenance of central sensitization in the rat, and the corresponding effects of early and late triptan therapy on allodynia during migraine. In the rat, triptan administration concomitant with chemical irritation of the dura effectively prevents the development of central sensitization. Similarly, treating patients with triptans early, within 60 min of the onset of migraine, effectively blocks the development of cutaneous allodynia. However, neither central neuronal sensitization in the rat, nor cutaneous allodynia in patients, can be reversed by late triptan treatment (2 hours after the application of sensitizing agent to the dura in the animal model, and 4 hours after the onset of migraine in allodonic patients). Most importantly, central sensitization appears to play a critical role in the management of migraine headache of allodonic patients. While non-allodonic patients can be rendered pain-free only if treated with triptans early, within 60 min of the onset of migraine, effectively blocks the development of cutaneous allodynia. However, neither central neuronal sensitization in the rat, nor cutaneous allodynia in patients, can be reversed by late triptan treatment (2 hours after the application of sensitizing agent to the dura in the animal model, and 4 hours after the onset of migraine in allodonic patients).

The findings that triptans cannot block ongoing sensitization in second-order trigeminovascular neurons is consistent with the evidence that these neurons do not possess the 5-HT₁D receptor that mediates the neuronal action of these drugs. If triptans do not abort migraine in the presence of allodynia (i.e., central sensitization), how do they render the patient pain-free in the absence of allodynia? The simple option would be a peripheral action of triptans that suppresses ongoing sensitization in the meningeal nociceptors that bombard the second-order neuron in the dorsal horn. However, the evidence...
ence shows that sensitized meningeal nociceptors are not inhibited by triptans. Thus, it appears that triptans abort migraine by a central, presynaptic action in the dorsal horn that blocks transmission of nociceptive signals between first- and second-order trigeminovascular neurons.

**Modulation of Central Sensitization**

A growing body of evidence suggests that migraine patients are mostly non-allodynic during the first years of their migraine experience, and are eventually destined to develop alodynia during their migraine attacks. It is therefore possible that repeated migraine attacks over the years have cumulative adverse consequences on the function of the trigeminovascular pathway, one of which is susceptibility to develop central sensitization. The threshold for a central trigeminovascular neuron to enter a state of sensitization depends on the balance between incoming nociceptive signals and their modulation by spinal and supraspinal pathways. Many of the modulatory supraspinal pathways converge on the PAG and

---

**Fig. 4.** Sensitization of central trigeminovascular neuron in the posterior thalamic nucleus believed to mediate extracranial alodynia. A: Expansion of cutaneous receptive field. B: Development of spontaneous activity. C: Enhanced responses to mechanical (top) and thermal (bottom) stimuli. Br: brush, H: habenula, IC: internal capsule, IS: inflammatory soup, Pi: pinch, PO: posterior thalamic nucleus, Pr: pressure, VPM: ventral posteromedial thalamic nucleus, VPL: ventral posterolateral thalamic nucleus.
rostral ventromedial medulla (RVM). Recent imaging studies have shown that the PAG is activated during migraine and that it is deposited with abnormally high levels of iron in patients with a long history of migraine, suggesting an abnormal neuronal functioning. Abnormal PAG functioning can either enhance activity of RVM neurons that facilitate pain transmission in the dorsal horn, or suppress activity of RVM neurons that inhibit pain transmission in the dorsal horn. This may enhance excitability and, therefore, promote responses of second-order trigeminovascular neurons to incoming nociceptive signals from the meninges, resulting in a reduced threshold for entering a state of central sensitization. Furthermore, the transition from episodic to chronic migraine that occurs in some patients over the years may involve a shift in the underlying pathophysiology from transient to chronic state of sensitization. Altered functions of modulatory supraspinal pain pathways can contribute to this progression in migraine pathophysiology.

**Brainstem Generator Theory**

A rather radical view on migraine pathophysiology originated from a 1987 report suggesting that the PAG may constitute a so-called “headache generator”. In that study, 15 out of 175 pain patients (8.5%) developed migraine-like headache immediately after undergoing craniotomy for electrodes implantation at (or near) the PAG. This point of view has promoted an interpretation that activation of the PAG during migraine is the source, rather than the consequence, of migraine pain. However, numerous studies have yielded overwhelming evidence to disprove the concept of the PAG as a “headache generator”. The first line of evidence is that persistent postoperative headache lasting 3 months or longer is routinely observed in 9-38% of patients undergoing craniotomy for a wide variety of procedures, with or without electrode placement. This crucial information was not available to Raskin et al. when they made the statement that “comparable headache syndromes have not been seen following craniotomy or burr hole placement performed for a variety of disorders.”

The second line of evidence comes from neuroimaging studies in humans and Fos expression studies in animals, demonstrating that PAG activation occurs in numerous non-headache pain paradigms. This indicates that PAG activation is a universal consequence of nociceptor activation anywhere in the body, which is perfectly consistent with the multiple input arriving at the PAG from nociceptive neurons through the length of the spinal cord. The third line of evidence is that electrical stimulation of the PAG produces a general whole-body pain relief. This indicates that modulation of pain by the PAG is non-specific, which is consistent with the anatomical evidence that individual RVM neurons project to multiple segments of the spinal cord and terminate in the dorsal horn. Finally, the fourth line of evidence is that stimulation of the PAG or RVM cannot generate firing in spinothalamic tract neurons; it can only increase or decrease firing in responses to noxious stimulation of their peripheral receptive fields.
Accordingly, it is activation of specific dorsal horn neurons by input they receive from peripheral nociceptors that determine where pain modulation is needed. In the case of migraine it is activation of trigeminovascular neurons in the medullary dorsal horn by inputs from meningeal nociceptors.

Activation of Meningeal Nociceptors

In spite of extensive research, the endogenous mechanisms by which meningeal nociceptors become activated have not yet been identified. We shall briefly review two hypotheses that attempt to describe endogenous cascades of events in the dura that may lead up to activation of meningeal nociceptors during the headache phase of migraine.

Neurogenic Inflammation Hypothesis

According to this hypothesis, meningeal nociceptors are activated by local release of endogenous inflammatory mediators through a process termed neurogenic inflammation.6,7,8 The process refers to a host of events, including local increase in blood flow, leakage of plasma protein from blood vessels, mast cell degranulation, and platelet aggregation. Neurogenic inflammation can be evoked experimentally by noxious stimulation of nociceptors that innervate a given tissue and the subsequent release of vasoactive neuropeptides such as substance P, neurokinin A, and CGRP.7,8 Similar markers of neurogenic inflammation and neuropeptide release have been induced in the rat dura by antidromic activation of meningeal afferents through electrical stimulation of the trigeminal ganglion.7,8,9 Support for the role of neurogenic inflammation in migraine comes from evidence that plasma protein extravasation and mast cell degranulation can be blocked in the rat by antimigraine drugs, such as ergot alkaloids and triptans,6,8,9 and by non-steroidal anti-inflammatory agents, such as indomethacin and acetylsalicylic acid.1,10,11

The neurogenic inflammation hypothesis does not explain, however, what causes the initial activation of meningeal nociceptors that triggers neurogenic inflammation in the dura. The next hypothesis has been proposed in an attempt to address this dilemma.

Cortical Spreading Depression Hypothesis

Cortical spreading depression (CSD) refers to a wave of brief excitation followed by prolonged (15-30 min) inhibition of neuronal activity that propagates slowly across the cortex at a rate of 2-6 mm/min. This neural phenomenon was first observed by Leao in the cortex of anesthetized rabbits,47 and later correlated with localized changes in blood flow that spread through the cortex at a similar rate.48 CSD has been implicated in the pathophysiology of migraine on the basis of neuroimaging studies showing slowly-migrating changes in cortical blood flow in patients tested during the visual aura phase of migraine.53-56 Since aura precedes the onset of headache by 20-30 min, it was postulated that CSD may lead up to the initial activation of meningeal nociceptors. But how would abnormal cortical activity produce an impact on dural pain fibers and blood vessels across the pia mater and arachnoids?

Direct electrophysiological evidence for the activation of trigeminovascular neurons by CSD were reported recently,62,63 the CSD hypothesis relies on two suppositions that are based on two independent sets of observation. One assumption is that molecules such as potassium ions, hydrogen ions, and glutamate that are released extracellularly during CSD in the cortex67,68,69 diffuse through the overlying meninges and activate meningeal nociceptors. The other assumption is that the induction of neurogenic inflammation in the dura by CSD is mediated by antidromic axonal reflex that propagates through sensory trigeminal axons collateral that innervate both the pia and dura. This assumption may be consistent with the finding that sensory denervation of the meninges blocks CSD-induced neurogenic inflammation in the dura.52 Anatomical evidence for the existence of individual trigeminal axons that innervate both the pia and dura are now available.92

Concluding Remarks: Implications for Migraine Therapy

Based on current understanding of migraine-associated cutaneous allodynia and the most probable mechanism of action of triptans in migraine therapy, it is recommended that patients with allodynia take triptans as early as possible into the attack before the emergence of any sign of allodynia. This recommendation is consistent with patients’ testimonies that triptans are much more likely to render them pain-free when taken early rather than late.

Nevertheless, most migraineurs testify that they routinely delay treatment until attacks are fully developed or the pain is severe. Justifying the delayed treatment are concerns about side effects, addiction, limits on supply imposed by prescribers, cost, and most commonly waiting to see if headache develops into a severe migraine attack.52 For these patients, one way to terminate migraine with allodynia and fully developed central sensitization is parenteral administration of COX1/COX2 inhibitors.84 Infusion of the COX1/COX2 inhibitor ketorolac in allodynic patients who already missed the critical period for triptan therapy terminated both the headache and allodynia provided that the patient had no history of using...
opioids to treat her/his migraines. In the rat, infusion of COX-1/COX-2 inhibitors blocked sensitization in meningeal nociceptors and suppressed ongoing sensitization in spinal trigeminovascular neurons, suggesting that parenteral nonsteroidal anti-inflammatory drug administration acts in the dorsal horn to inhibit the central neurons directly and reduce the synaptic input from the peripheral trigeminovascular neuron.4,9

Though impractical as a routine migraine therapy, parenteral nonsteroidal anti-inflammatory drug administration should be useful as a non-narcotic rescue therapy for migraine in the setting of the emergency department. Patients who use an opioid therapy over extended period of time are at high risk of developing medication-overuse headache and low response to non-narcotic drugs. The rational for recommending against the use of opioids in allodynic migraine patients is based on evidence that opioids can facilitate sensitization in the dorsal horn6,10 through: 1) upregulation of NMDA receptors function, 2) downregulation of glutamate transporters, 3) production of nitric oxide, 4) activation of spinal glia, and 5) increase extracellular level of prostaglandins.

Conflicts of Interest

The authors have no financial conflicts of interest.

Acknowledgements

This research was supported by NIH grants NS-051484, NS-056195 and NS069847.

REFERENCES

1. Anthony M. The treatment of migraine—old methods, new ideas. Aust Fam Physician 1993;22:1434-1435, 1438-1439, 1442-1443.
2. Blau JN, Dexter SL. The site of pain origin during migraine attacks. Cephalalgia 1981;1:143-147.
3. Raanvainen BK, Jensen R, Schnoll M, Olesen J. Epidemiology of headache in a general population—a prevalence study. J Clin Epidemiol 1991;44:1147-1157.
4. Wolff HG. Headache and Other Head Pain. 2nd ed. New York: Oxford University Press, 1963.
5. Wolff HG, Tunis MM, Goodell H. Studies on headache: evidence of damage and changes in pain sensitivity in subjects with vascular headaches of the migraine type. AMA Arch Intern Med 1953;92:478-484.
6. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993;5:159-177.
7. Zwetsloot CP, Caekebeke JF, Jensen JC, Odink J, Ferrari MD. Blood flow velocity changes in migraine attacks—a transcerebral Doppler study. Cephalalgia 1991;11:103-107.
8. Ray BS, Wolff HG. Experimental studies on headache. Pain-sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-856.
9. Penfield W, McNaughton F. Dural headache and innervation of the dura mater. Arch Neurol Psychiatry 1940;44:43-75.
10. Keller JT, Saunders MC, Bedak A, Jollis JG. Innervation of the posterior fossa dura of the cat. Brain Res Bull 1985;14:97-102.
11. Andreas KH, von Düring M, Muszynski K, Schmidt RF. Nerve fibres and their terminals of the dura mater encephali of the rat. Anat Embryol (Berl) 1987;175:289-301.
12. Mayberg M, Langer RS, Zervas NT, Moskowitz MA. Perivascular meningeal projections from cat trigeminal ganglion: possible pathway for vascular headaches in man. Science 1981;213:228-230.
13. Uddman R, Edvinsson L, Eklman R, Kingman T, McCalloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985;62:131-136.
14. Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. J Comp Neurol 1991;309:515-534.
15. Strassman A, Mason P, Moskowitz M, Maciewicz R. Response of brainstem trigeminal neurons to electrical stimulation of the dura. Brain Res 1986;379:242-250.
16. Davis KD, Dostrovsky JO. Activation of trigeminal brain-stem nociceptive neurons by dural artery stimulation. Pain 1986;25:395-401.
17. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brain and upper cervical spinal cord of the cat. Brain Res 1991;114:1001-1011.
18. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 1993;629:95-102.
19. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasopressin. Neuropeptides 1990;16:69-75.
20. Strassman AM, Mineta Y, Nos BP. Distribution of fos-like immunoreactivity in the medullary and upper cervical dorsal horn produced by stimulation of dural blood vessels in the rat. J Neurosci 1994;14:3725-3735.
21. Davis KD, Dostrovsky JO. Responses of feline trigeminal spinal tract nucleus neurons to stimulation of the middle meningeal artery and sagittal sinus. J Neurophysiol 1988;59:648-666.
22. Benjamini L, Levy MJ, Lasalander MP, Knight YE, Akerman S, Classey JD, et al. Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study. Neurobiol Dis 2004;16:500-505.
23. Malick A, Jakubowski M, Elmiquist JK, Saper CB, Burstein R. A neurohistochemical blueprint for pain-induced loss of appetite. Proc Natl Acad Sci U S A 2001;98:9930-9935.
24. Levy D, Strassman AM. Mechanical response properties of A and C primary afferent neurons innervating the rat intracranial dura. J Neurophysiol 2002;88:3021-3031.
25. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998;79:964-982.
26. Yamamura H, Malick A, Chamberlin NL, Burstein R. Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. J Neurophysiol 1999;81:479-493.
27. Zagami AS, Lambert GA. Stimulation of cranial vessels excites nociceptive neurons in several thalamic nuclei of the cat. Exp Brain Res 1990;81:552-566.
28. Davis KD, Dostrovsky JO. Properties of feline thalamic neurons activated by stimulation of the middle meningeal artery and sagittal sinus. Brain Res 1988;454:89-100.
29. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT1B/D) receptor agonist zolmitriptan (31IC90): are brain stem sites therapeutic target in migraine? Pain 1996;67:355-359.
30. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996;119:249-256.
31. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The
spinal cord processing of input from the superior sagittal sinus pathway and modulation by ergot alkaloids. Brain Res 1992;597:321-330.

32. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;384:560-564.

33. Beck PW, Handwerker HO. Bradykinin and serotonin effects on various types of cutaneous nerve fibers. Pflogars Arch 1974;347:209-222.

34. Davis KD, Meyer RA, Campbell JN. Chemosensitivity and sensitization of nociceptive afferents that innervate the hairy skin of monkey. J Neurophysiol 1993;69:1071-1081.

35. Mizumura K, Sato J, Kumazawa T. Effects of prostaglandins and other putative chemical intermediaries on the activity of canine testicular polymodal receptors studied in vitro. Pflogars Arch 1989;408:565-572.

36. Neugebauer Y, Schaible HG, Schmidt RF. Sensitization of articular afferents to mechanical stimuli by bradykinin. Pflogars Arch 1989;415:330-335.

37. Steen KH, Reeh PW, Anton F, Handwerker HO. Protons selectively induce lasting excitation and sensitization to mechanical stimulation of nociceptors in rat skin, in vitro. J Neurosci 1992;12:86-95.

38. Armstrong D, Jepson JB, Keele CA, Stewart JW. Pain-producing substance in human epidermal exudates and plasma. J Physiol 1957;135:350-370.

39. Guzman F, Braun C, Lim RK. Visceral pain and the pseudoaffection of interoceptors. Arch Int Pharmacodyn Ther 1962;136:355-384.

40. Hollander W, Michelson AL, Wilkins RW. Serotonin and antiseroconc. J Neurophysiol 1957;20:246-255.

41. Sicuteri F. Vasoneuroactive substances and their implication in vascular pain. Res Clin Stud Headache 1967;1:6-45.

42. Living e On Megrin, Sick-Headache, and Some Allied Disorders: A Contribution to the Pathology of Nerve-Storms. London: J. and A. Churchill, 1873.

43. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 1960;23:23-32.

44. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-624.

45. Craig AD, Dubovsky JO. Thermoreceptive lamin I trigeminothalamic neurons project to the nucleus submedius in the cat. Exp Brain Res 1991;85:470-474.

46. Strassman AM, Potrebic S, Maciewicz RJ. Anatomical properties of brainstem trigeminal neurons that respond to electrical stimulation of dural blood vessels. J Comp Neurol 1994;346:349-365.

47. Ebersberger A, Reinkek M, Reeh PW, Handwerker HO. Recordings from brain stem neurons responding to chemical stimulation of the subarachnoid space. J Neurophysiol 1997;77:3122-3133.

48. Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Har-greaves R, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 2010;68:81-91.

49. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003;26:696-705.

50. Burstein R, Jakubowski M. Analgesic tritran action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004;55:27-36.

51. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26.

52. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003;23:10988-10997.

53. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 2004;101:4274-4279.

54. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003;43:1075-1079.

55. Fields HL. Pain: an unpleasant topic. Pain 1999;Suppl 6:561-569.

56. Weiller C, May A, Linmuth V, Jäntner M, Kaube H, Schayek RV, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-660.

57. Welch KM, Nageh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001;41:629-637.

58. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002;25:319-325.

59. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987;27:416-420.

60. Bahra A, Matharu MS, Bachel C, Frackowiak RS, Goudsby PJ. Brainstem activation specific to migraine headache. Lancet 2001;357:1016-1017.

61. Schaller B, Baumann A. Headache after removal of vestibular schwannoma via the retrosigmoid approach: a long-term follow-up study. Otolaryngol Head Neck Surg 2003;128:387-395.

62. Harner SG, Beatty CW, Ebersold MJ. Headache after acoustic neuroma excision. Am J Otol 1993;14:552-555.

63. Gökalp HZ, Arasil E, Ergunoglu A, Egegen N, Deda H, Cerci A. Temporal meningeomas. Neurosurgery 1995;36:51; discussion 51.

64. Kaur A, Selwa L, Fromes G, Ross DA. Persistent headache after supratentorial craniootomy. Neurosurgery 2000;47:633-636.

65. Gee JR, Ishaq Y, Vijayan N. Postcraniotomy headache. Headache 2003;43:276-278.

66. Derbyshire SW, Jones AK, Creed F, Star T, Meltzer C, Townsend DW, et al. Cerebral responses to noxious thermal stimulation in chronic low back pain patients and normal controls. Neuroimage 2002;16:158-168.

67. Petrovic P, Ingvar M, Stone-Elander S, Petersson KM, Hansson P. A PET activation study of dynamic mechanical allodynia in patients with mononeuropathy. J Neurosurg 1999;83:459-470.

68. Hsieh JC, Stähle-Bäckdahl M, Hägermark O, Stone-Elander S, Rosenquist G, Ingvar M. Traumatic nociceptive pain activates the hypothalamic-pituitary-adrenal axis in a positron emission tomography study. Pain 1996;64:303-314.

69. Jadarola MJ, Berman KF, Zeffer TA, Byas-Smith MG, Gracely RH, Max MB, et al. Neural activation during acute capsaicin-evoked pain and allodynia assessed with PET. Brain Res 2001:81-91.

70. Bandler R, Keay KA, Floyd N, Price J. Central circuits mediating pain and allodynia assessed with PET. Brain Res 2001:81-91.

71. Hosobuchi Y, Adams JE, Linchitz R. Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. Science 1977;197:183-186.

72. Basbaum AI, Fields HL. Endogenous pain control mechanisms: review and hypothesis. Ann Neurol 1978;4:451-462.

73. Holstege G, Vertes RP, Waltzer R. Spinal projections of the gianticellular reticular formation in the rat. Evidence for projections from different areas to lamina I and II and lamina IX. Brain Res 1980;208:95-104.

74. Harner SG, Beatty CW, Ebersold MJ. Headache after acoustic neuroma excision. Am J Otol 1993;14:552-555.

75. Martin GF, Vertes RP, Walterz R. Spinal projections of the gigantocellular reticular formation in the rat. Evidence for projections from different areas to laminae I and II lamina IX. Brain Res 1985;35:154-162.

76. Fields HL, Malick A, Burstein R. Dorsal horn projection targets of ON and OFF cells in the rostral ventromedial medulla. J Neurophysiol 1995;74:1742-1759.

77. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984;16:157-168.

78. Holzer P. Local effector functions of capsaicin-sensitive sensory fibers. J Clin Neurol 2012;8:89-99.
nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988;24:739-768.
78. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987;7:4129-4136.
79. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991;44:97-112.
80. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR 43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-206.
81. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989;165:251-258.
82. Leão AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:359-390.
83. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994;117:199-210.
84. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 2001;98:4687-4692.
85. Bowyer SM, Aurora KS, Moran JE, Tepley N, Welch KM. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001;50:582-587.
86. James MF, Smith JM, Boniface SJ, Huang CL, Leslie RA. Cortical spreading depression and migraine: new insights from imaging? Trends Neurosci 2001;24:266-271.
87. Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 2011;69:855-865.
88. Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 2010;30:8807-8814.
89. Brinley FJ Jr, Kandel ER, Marshall WH. Potassium outflux from rabbit cortex during spreading depression. J Neurophysiol 1960;23:246-256.
90. Rapoport SI, Marshall WH. Measurement of Cortical Ph in Spreading Cortical Depression. Am J Physiol 1964;206:1177-1180.
91. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsically activated brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-142.
92. Kosaras B, Jakubowski M, Kainz V, Burstein R. Sensory innervation of the calvarial bones of the mouse. J Comp Neurol 2000;515:331-348.
93. Foley KA, Cady R, Martin V, Adelman J, Diamond M, Bell CF, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005;45:538-545.
94. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005;45:850-861.
95. Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 2007;148:573-583.
96. Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: a review. Int J Clin Pharmacol Ther 2004;42:191-203.
97. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. GliA: novel counter-regulators of opioid analgesia. Trends Neurosci 2005;28:661-669.
98. Mayer DJ, Mao J, Holt J, Price DD. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci U S A 1999;96:7731-7736.
99. Ozawa T, Nakagawa T, Shige K, Minami M, Satoh M. Changes in the expression of glial glutamate transporters in the rat brain accompanied with morphine dependence and naloxone-precipitated withdrawal. Brain Res 2001;905:254-258.